Skip to content
HowShorted

Alaunos Therapeutics, Inc. short interest in 2021

In 2021, Alaunos Therapeutics, Inc.'s disclosed short interest ran from 15.20% of shares outstanding on 15 Jan 2021 to 15.75% on 31 Dec 2021, a change of +0.55 percentage points. The year's high was 18.38% on 31 Mar 2021 and its low 14.90% on 15 Oct 2021, averaging 16.32% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 34.57 days on 28 May 2021. Full history: Alaunos Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Alaunos Therapeutics, Inc. in 2021

2021 in figures

Start of year
15.20% (15 Jan 2021)
End of year
15.75% (31 Dec 2021)
Change
+0.55 pp
High
18.38% (31 Mar 2021)
Low
14.90% (15 Oct 2021)
Average
16.32%
Highest days to cover
34.57 (28 May 2021)
SEC filings marked
7

Every report in 2021

Alaunos Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202115.20%13.80
29 Jan 202114.97%10.18
12 Feb 202115.84%9.53
26 Feb 202116.42%16.91results (8-K)
15 Mar 202116.51%13.1010-K filed
31 Mar 202118.38%17.60
15 Apr 202118.21%32.78
30 Apr 202118.27%33.29
14 May 202117.98%25.6710-Q filed, results (8-K)
28 May 202117.33%34.57
15 Jun 202117.31%15.13
30 Jun 202116.34%16.06
15 Jul 202116.55%29.28
30 Jul 202116.92%28.06
13 Aug 202116.40%18.14results (8-K), 10-Q filed
31 Aug 202115.90%15.13
15 Sep 202115.77%3.32
30 Sep 202115.06%11.63
15 Oct 202114.90%17.90
29 Oct 202115.15%18.28
15 Nov 202115.14%19.8510-Q filed
30 Nov 202115.38%13.56
15 Dec 202115.97%12.46
31 Dec 202115.75%12.59

See also: Alaunos Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.